Tag: biotechnology
-
Biotech, Research Institute Partner on Gene Therapies
13 May 2015. A collaboration between a U.S. biotechnology company and French research institute is enhancing current techniques to allow patients with rare diseases to receive multiple doses of gene therapies. Selecta Biosciences in Watertown, Masachusetts and Généthon in Evry, France plan to co-develop and co-own the results of their partnership, but financial details of…
-
RNA Therapies Developer Spins-Off Rare Disease Venture
12 May 2015. Moderna Therapeutics, a developer of RNA-based treatments, is starting a new company to design therapies with its technology to address rare diseases. Financial details of the spin-off company Elpidera LLC, the third such venture launched by Moderna, were not disclosed. Moderna, a biotechnology enterprise in Cambridge, Massachusetts, develops medications that use genetic…
-
Gene Editing Harnessed to ID Cancer Targets
12 May 2015. Researchers from Cold Spring Harbor Lab in New York developed a technique that reveals targets for leukemia drugs with an emerging gene editing technology. A team from the lab of geneticist Christopher Vakoc published its findings yesterday in the journal Nature Biotechnology (paid subscription required). Vakoc and colleagues study proteins regulating chromatin,…
-
Clinical Trial Testing West Nile Vaccine
7 May 2015. A vaccine for West Nile virus, a seasonal infection spread by mosquitoes, is being tested for safety in an early stage clinical trial. The vaccine, code-named HydroVax-001, is being developed in the lab of microbiologist Mark Slifka at Oregon Health and Science University in Beaverton and commercialized by Najit Technologies Inc., a…
-
Trial Underway Testing RNA Therapy for Rare Liver Disorder
5 May 2015. An early-stage clinical trial is testing a therapy derived from genetic material to treat alpha-1 antitrypsin deficiency, a rare inherited disease affecting the liver and lungs. The therapy, code-named ARC-AAT, is developed by Arrowhead Research Corporation, a biopharmaceutical company in Pasadena, California. Alpha-1 antitrypsin deficiency, or AATD, is caused by a mutation…
-
Cancer Therapy Spin-Off Gets $2M Small Business Grant
4 May 2015. A three year-old company started by a University at Buffalo microbiologist received a $2 million grant to develop an antibody into a clinical treatment for breast and other types of cancer. For-Robin in Williamsville, New York, received the two-year award from National Cancer Institute, part of National Institutes of Health, under the…
-
Stem Cells Treat Vision Disorders in Animal Tests
4 May 2015. Tests with lab rats of a therapy for degenerating retinas in the eyes, show the treatments derived from human embryonic stem cells can restore visual functions. Results of the treatments, developed by Cell Cure Neurosciences Ltd., are scheduled to be reported today by a research team from Oregon Health and Science University…
-
Cancer Biotech Raising $147 Million in IPO
30 April 2015. Blueprint Medicines, a developer of cancer therapies that block enzymes supporting tumor growth, is raising some $146.7 million in its initial public stock offering. The Cambridge, Massachusetts enterprise, listed on the NASDAQ exchange under the symbol BPMC, issued 8.15 million shares at $18.00. The company began trading today with its share price…
-
Plant Science Biotech Gets Genome Editing Technology
16 April 2015. Cellectis Plant Sciences, a biotechnology company in Minnesota developing higher quality crops through genetic engineering, licensed CRISPR genome editing technology from University of Minnesota. Financial details of the agreement between Cellectis and the university were not disclosed. The technology licensed by Cellectis covers techniques known as CRISPR, short for clustered, regularly interspaced short…
-
Aduro Biotech Raises $108 million in IPO
15 April 2015. Aduro Biotech Inc., a developer of immunotherapies to treat cancer, issued its initial public stock offering today that expects to net the company some $108 million, after issuing 7 million shares priced at $17.00. The Berkeley, California enterprise trades on the Nasdaq exchange under symbol ADRO. As of the Nasdaq closing bell…